Olfr575 Inhibitors
Olfr575, belonging to the olfactory receptor family, is intricately involved in olfaction, playing a pivotal role in detecting specific odorants and initiating signaling cascades. This receptor is essential for the perception of distinct smells, and its regulation is critical for proper olfactory function. Inhibition of Olfr575 can be achieved through both direct and indirect means. The presented chemicals act as indirect inhibitors by targeting key cellular pathways associated with Olfr575, ultimately leading to modified gene expression patterns. For instance, Gefitinib disrupts the EGFR signaling pathway, indirectly downregulating Olfr575 expression through modulation of critical components in the pathway. Selumetinib, a MEK inhibitor, impacts the MAPK pathway, influencing Olfr575 indirectly by altering the MEK-ERK signaling axis and downstream molecular effectors.
SB-431542, as a TGF-β receptor inhibitor, attenuates Smad signaling, indirectly inhibiting Olfr575 by interfering with the TGF-β pathway. Additionally, Wortmannin, PD98059, Rapamycin, LY294002, AZD5363, and BAY 11-7082 target PI3K, MAPK, mTOR, Akt, and NF-κB pathways, respectively, leading to indirect downregulation of Olfr575 expression through disruptions in the associated molecular cascades. In summary, Olfr575 is a crucial player in olfactory signaling, contributing to the detection and processing of specific odorants. The indirect inhibitors discussed here provide a systematic approach to modulate Olfr575 expression by targeting key cellular pathways associated with olfaction. These insights into the regulation of Olfr575 offer valuable avenues for further exploration and understanding of olfactory receptor modulation in cellular responses.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib acts as an EGFR inhibitor, indirectly inhibiting Olfr575. By disrupting the EGFR signaling pathway, it alters downstream cascades, leading to indirect downregulation of Olfr575 expression through modulation of essential molecular components in the pathway. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib, a MEK inhibitor, indirectly influences Olfr575 by targeting the MAPK pathway. This disruption leads to altered cellular responses, affecting Olfr575 expression through interference with the MEK-ERK signaling axis and downstream molecular effectors. | ||||||
SB 431542 | 301836-41-9 | sc-204265 sc-204265A sc-204265B | 1 mg 10 mg 25 mg | $82.00 $216.00 $416.00 | 48 | |
SB-431542 functions as a TGF-β receptor inhibitor, attenuating downstream Smad signaling. This indirectly inhibits Olfr575 by interfering with the TGF-β pathway, leading to altered cellular responses and reduced expression of the target gene. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin, a PI3K inhibitor, indirectly regulates Olfr575 by disrupting the PI3K/Akt pathway. This leads to modified intracellular signaling, impacting Olfr575 expression through interference with the associated molecular cascades and downstream effectors. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059, a MEK inhibitor, indirectly inhibits Olfr575 by disrupting the MAPK pathway. Through the inhibition of MEK, PD98059 alters the ERK signaling cascade, resulting in indirect downregulation of Olfr575 expression by interfering with its associated molecular pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin, an mTOR inhibitor, indirectly influences Olfr575 by modulating the mTOR signaling pathway. This indirect inhibition leads to altered cellular responses, affecting Olfr575 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a PI3K inhibitor, indirectly influences Olfr575 by modulating the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr575 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
AZD5363 | 1143532-39-1 | sc-503190 | 5 mg | $309.00 | ||
AZD5363, an Akt inhibitor, indirectly inhibits Olfr575 by targeting the PI3K/Akt/mTOR pathway. This inhibition results in altered intracellular signaling, impacting Olfr575 expression through disruptions in the associated molecular cascades and downstream effectors. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $62.00 $85.00 $356.00 | 155 | |
BAY 11-7082, an NF-κB inhibitor, indirectly inhibits Olfr575 by modulating the NF-κB signaling pathway. This leads to altered cellular responses, affecting Olfr575 expression through disruptions in the associated molecular cascades and downstream targets. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib acts as a multikinase inhibitor, impacting the Ras/Raf/MEK/ERK pathway. By disrupting this pathway, Olfr575 expression is indirectly downregulated. The inhibition is mediated through interference with key signaling molecules in the mentioned pathway. | ||||||